Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid Screen for Tyrosine Kinase Inhibitor Resistance Mutations and Substrate Specificity

24 Jul 2019

Abstract excerpt

We present a rapid and high-throughput yeast and flow cytometry based method for predicting kinase inhibitor resistance mutations and determining kinase peptide substrate specificity. Despite the widespread success of targeted kinase inhibitors as cancer therapeutics, resistance mutations arising within the kinase domain of an oncogenic target present a major impediment to sustained treatment efficacy. Our...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31339688
DOI: 10.1021/acschembio.9b00283

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid Screen for Tyrosine Kinase Inhibitor Resistance Mutations and Substrate SpecificityPMID 31339688Read ↗

Profiling of the drug resistance of thousands of Src tyrosine kinase mutants uncovers a regulatory network that couples autoinhibition to catalytic domain dynamicsSemantic proximity Read ↗

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.Semantic proximity Read ↗

A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein.Semantic proximity Read ↗

Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing.Semantic proximity Read ↗

The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.Semantic proximity Read ↗

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.Semantic proximity Read ↗

Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor ScreeningSemantic proximity Read ↗

Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.Semantic proximity Read ↗

T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib.Semantic proximity Read ↗

BCR-ABL1 compound mutations drive ponatinib resistance.Semantic proximity Read ↗

A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors.Semantic proximity Read ↗

Reprogramming protein kinase substrate specificity through synthetic mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.